{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/adverse-drug-reactions/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"6474141f-1642-5857-9d25-033f3b7503f0","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 3cd26a0d-7da2-4ac0-8a27-adf1eee03a2f --><h2>Update</h2><!-- end field 3cd26a0d-7da2-4ac0-8a27-adf1eee03a2f -->","summary":null,"htmlStringContent":"<!-- begin item 53660708-4aea-48ee-a2e0-1251769d53fc --><!-- end item 53660708-4aea-48ee-a2e0-1251769d53fc -->","topic":{"id":"5891f47f-d14e-5ade-b43e-09ab2ee894c3","topicId":"fb7af4be-ae9d-4213-b2ca-ca17ddb868c1","topicName":"Adverse drug reactions","slug":"adverse-drug-reactions","lastRevised":"Last revised in March 2017","chapters":[{"id":"78737b02-a5d5-5686-924f-3bd67a984373","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"3124c32f-664e-57ef-805a-95067102ad32","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"23e3d730-4bbb-5a3a-bd97-77a17bee3f53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0974ec45-5b01-515b-b02e-5cad23aacea1","slug":"changes","fullItemName":"Changes"},{"id":"6474141f-1642-5857-9d25-033f3b7503f0","slug":"update","fullItemName":"Update"}]},{"id":"5bad1097-961b-5653-8f9b-6456f05b7836","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6be883ff-72cf-54e9-b064-31f4df584e67","slug":"goals","fullItemName":"Goals"},{"id":"c6cc81cc-134f-5d98-b79c-967bf65bddd3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"95dab13c-419c-5de3-b7fd-95118f8b48e5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d675aba3-9d84-5b1a-9c2b-79cc7bcab6c3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd63cb73-82b3-5c83-bea6-b82fa98f7888","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"977ca222-407c-5643-a723-eeee2b2f6c0f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b68bacaa-d4b5-58a7-b9d6-46bf7c82f8ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"26252f90-7908-554e-8535-a49168c8bf4a","slug":"definition","fullItemName":"Definition"},{"id":"68cfd9ca-f6d9-582b-a898-39bd0927455f","slug":"categorization-of-adrs","fullItemName":"Categorization of ADRs"},{"id":"2bf3267e-f0ed-5301-b659-3a0d290262bc","slug":"health-financial-implications-of-adrs","fullItemName":"Health and financial implications of ADRs"},{"id":"804b9155-4dc6-574d-b5b3-3e320dd07967","slug":"monitoring-adverse-drug-reactions","fullItemName":"Monitoring adverse drug reactions"}]},{"id":"753ee7eb-1c21-5cf5-8e2e-e0e3ebd8be4a","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d7dbb3f-b730-5e84-aea1-49ed9234a126","slug":"adverse-drug-reactions","fullItemName":"Scenario: Adverse drug reactions"}]},{"id":"95500d82-4a44-5f81-befc-15cfb88abd53","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"77a8b838-04cb-5545-affe-c92faa19e1bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dfa6f9b0-4f82-5b25-99fb-5ce802d731e8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f85a17d1-c7b8-5ebf-a80c-88c2f6c69eff","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5aee896a-ac4b-5a54-bde2-0577412d6418","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"8054ea0e-276d-5167-818e-fec1d38114aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1a62db49-0d92-514d-9a4a-dfa05227ec25","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"86d8d508-d776-5c0a-be24-6df70fb79006","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"23e3d730-4bbb-5a3a-bd97-77a17bee3f53","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"687b6b00-2f3b-57f9-9d6e-168bb00f9ce0","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 674c23d4-9030-428d-b7f4-805b47403198 --><h3>New evidence</h3><!-- end field 674c23d4-9030-428d-b7f4-805b47403198 -->","summary":null,"htmlStringContent":"<!-- begin item 37a1b230-69c3-40fd-8bec-3acb8b6da3cd --><!-- begin field acf912f7-0e8b-4953-b648-7422c0622bfc --><h3>Evidence-based guidelines</h3><!-- end field acf912f7-0e8b-4953-b648-7422c0622bfc --><!-- begin field 7ff58c06-6c22-4e90-a01b-bc908d1c8ba4 --><p>No new guidelines published since 1 March 2017.</p><!-- end field 7ff58c06-6c22-4e90-a01b-bc908d1c8ba4 --><!-- begin field 25a67b40-4db6-49bd-91b1-0de215792a66 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 25a67b40-4db6-49bd-91b1-0de215792a66 --><!-- begin field 85afa8e5-dee3-4728-b56d-16890bf029a0 --><p>No new HTAs since 1 March 2017.</p><!-- end field 85afa8e5-dee3-4728-b56d-16890bf029a0 --><!-- begin field d7fd4fcd-fd0b-4ccb-9adb-44a64e7813b3 --><h3>Economic appraisals</h3><!-- end field d7fd4fcd-fd0b-4ccb-9adb-44a64e7813b3 --><!-- begin field f1177bd4-5c31-48bb-a3f6-a7daae381191 --><p>No new economic appraisals relevant to England since 1 March 2017.</p><!-- end field f1177bd4-5c31-48bb-a3f6-a7daae381191 --><!-- begin field 5fa72a95-e5ca-4852-8fa1-e7435162e517 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 5fa72a95-e5ca-4852-8fa1-e7435162e517 --><!-- begin field baae6764-f173-4b5b-8166-24febe0fbcef --><p>No new systematic reviews published since 1 March 2017.</p><!-- end field baae6764-f173-4b5b-8166-24febe0fbcef --><!-- begin field a509e80b-90fa-47ae-b9c8-34d5f3463949 --><h3>Primary evidence</h3><!-- end field a509e80b-90fa-47ae-b9c8-34d5f3463949 --><!-- begin field b5beeec8-7319-46b1-813b-3c3e033aa1ef --><p>No new randomized controlled trials published in the major journals since 1 March 2017.</p><!-- end field b5beeec8-7319-46b1-813b-3c3e033aa1ef --><!-- end item 37a1b230-69c3-40fd-8bec-3acb8b6da3cd -->","subChapters":[]},{"id":"82123456-93d2-5a3e-bef6-71c0e6de5d8a","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 65a5a885-6056-4761-b9c9-b41f6795dd3e --><h3>New policies</h3><!-- end field 65a5a885-6056-4761-b9c9-b41f6795dd3e -->","summary":null,"htmlStringContent":"<!-- begin item d2413e6f-7c98-43f3-83e3-eacfd5e71203 --><!-- begin field 6f8c50eb-0cad-4dfb-b4e9-4ddd2f348c81 --><p>No new national policies or guidelines since 1 March 2017.</p><!-- end field 6f8c50eb-0cad-4dfb-b4e9-4ddd2f348c81 --><!-- end item d2413e6f-7c98-43f3-83e3-eacfd5e71203 -->","subChapters":[]},{"id":"120256dd-3079-5545-8ebd-01b482ae3f11","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field ccf34b0e-5d86-4bc8-9f7f-963cf87a3621 --><h3>New safety alerts</h3><!-- end field ccf34b0e-5d86-4bc8-9f7f-963cf87a3621 -->","summary":null,"htmlStringContent":"<!-- begin item 96790fbd-1cff-46ba-bd9c-2c68b61e1131 --><!-- begin field b7bf5ba9-7f22-43ae-80a4-763a29364d97 --><p>No new safety alerts since 1 March 2017.</p><!-- end field b7bf5ba9-7f22-43ae-80a4-763a29364d97 --><!-- end item 96790fbd-1cff-46ba-bd9c-2c68b61e1131 -->","subChapters":[]},{"id":"65c37364-0329-5e84-aae6-a6e917219893","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 798cdd3f-0c1b-46d8-83f9-f96f9972c633 --><h3>Changes in product availability</h3><!-- end field 798cdd3f-0c1b-46d8-83f9-f96f9972c633 -->","summary":null,"htmlStringContent":"<!-- begin item 69a3301f-4ad7-4e2d-94ce-276678463551 --><!-- begin field ab2349a7-577e-463b-8c26-ca6ad174a209 --><p>No changes in product availability since 1 March 2017.</p><!-- end field ab2349a7-577e-463b-8c26-ca6ad174a209 --><!-- end item 69a3301f-4ad7-4e2d-94ce-276678463551 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}